OncoMyx Therapeutics, a startup launched from Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement. The company's MYXV platform, spun out from ASU, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/08/21 | $50,000,000 | Series B |
B Capital Group Boehringer Ingelheim Venture Fund City Hill Ventures Delos Capital Korea Investment Partners Lumira Capital LYZZ Capital Madison Partners Xeraya Capital | undisclosed |
